HealthCap
HealthCap is a venture capital firm founded in 1996 and based in Stockholm, Sweden, specializing in investments within the life sciences sector. With over €800 million in committed capital, it is one of the largest providers of venture capital in Europe focused on healthcare and biotechnology. The firm targets both early and late-stage investments, seeking transformative therapies and innovative technologies that address high unmet medical needs. HealthCap invests globally, primarily in pharmaceuticals, biotechnology, and related fields, and aims to act as a lead investor, often acquiring minority stakes and seeking board representation in its portfolio companies. Since its inception, HealthCap has managed multiple funds and has completed numerous investments, demonstrating its commitment to advancing medical practices and improving patient outcomes.
Carisma Therapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing innovative cellular immunotherapies for the treatment of solid tumors. Founded in 2016, the company specializes in engineering chimeric antigen receptor (CAR) macrophages and monocytes, which are types of white blood cells that play a crucial role in the immune response. By harnessing advances in macrophage biology and adoptive cell transfer, Carisma aims to enhance cancer therapies, allowing for more effective treatment options for patients with solid tumors. The company is in the clinical stage of development, working to translate its proprietary technology into transformative therapies for various serious diseases.
Carisma Therapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing innovative cellular immunotherapies for the treatment of solid tumors. Founded in 2016, the company specializes in engineering chimeric antigen receptor (CAR) macrophages and monocytes, which are types of white blood cells that play a crucial role in the immune response. By harnessing advances in macrophage biology and adoptive cell transfer, Carisma aims to enhance cancer therapies, allowing for more effective treatment options for patients with solid tumors. The company is in the clinical stage of development, working to translate its proprietary technology into transformative therapies for various serious diseases.
Carisma Therapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing innovative cellular immunotherapies for the treatment of solid tumors. Founded in 2016, the company specializes in engineering chimeric antigen receptor (CAR) macrophages and monocytes, which are types of white blood cells that play a crucial role in the immune response. By harnessing advances in macrophage biology and adoptive cell transfer, Carisma aims to enhance cancer therapies, allowing for more effective treatment options for patients with solid tumors. The company is in the clinical stage of development, working to translate its proprietary technology into transformative therapies for various serious diseases.
Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases. Centyrins are small, non-antibody protein scaffolds that can be expressed as multi-specifics with novel therapeutic mechanisms of action. Centyrins are also ideal for the targeted delivery of complex drug payloads, including nucleic acids.
Carisma Therapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing innovative cellular immunotherapies for the treatment of solid tumors. Founded in 2016, the company specializes in engineering chimeric antigen receptor (CAR) macrophages and monocytes, which are types of white blood cells that play a crucial role in the immune response. By harnessing advances in macrophage biology and adoptive cell transfer, Carisma aims to enhance cancer therapies, allowing for more effective treatment options for patients with solid tumors. The company is in the clinical stage of development, working to translate its proprietary technology into transformative therapies for various serious diseases.
Carisma Therapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing innovative cellular immunotherapies for the treatment of solid tumors. Founded in 2016, the company specializes in engineering chimeric antigen receptor (CAR) macrophages and monocytes, which are types of white blood cells that play a crucial role in the immune response. By harnessing advances in macrophage biology and adoptive cell transfer, Carisma aims to enhance cancer therapies, allowing for more effective treatment options for patients with solid tumors. The company is in the clinical stage of development, working to translate its proprietary technology into transformative therapies for various serious diseases.
Carisma Therapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing innovative cellular immunotherapies for the treatment of solid tumors. Founded in 2016, the company specializes in engineering chimeric antigen receptor (CAR) macrophages and monocytes, which are types of white blood cells that play a crucial role in the immune response. By harnessing advances in macrophage biology and adoptive cell transfer, Carisma aims to enhance cancer therapies, allowing for more effective treatment options for patients with solid tumors. The company is in the clinical stage of development, working to translate its proprietary technology into transformative therapies for various serious diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.